<DOC>
	<DOCNO>NCT01860976</DOCNO>
	<brief_summary>The purpose study compare subcutaneous Abatacept placebo treatment psoriatic arthritis</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Abatacept Adults With Active Psoriatic Arthritis</brief_title>
	<detailed_description>ASTRAEA=Active PSoriaTic ARthritis RAndomizEd TriAl</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects least 18 year age diagnosis PsA Classification Criteria Psoriatic Arthritis ( CASPAR ) Subjects active PsA show minimum ≥3 swollen joint ≥3 tender joint ( 66/68 joint count ) screen randomization/Day 1 ( prior study drug administration ) . At least one swollen joint must digit hand foot Subjects least one confirm ≥2 cm target lesion plaque psoriasis region body evaluate exclude axilla , genitals , groin , palm , sol Subjects must inadequate response intolerance least one nonbiologic diseasemodifying antirheumatic drug ( DMARD ) Subjects may expose TNFi therapy . Subjects may discontinue reason ( inadequate response , intolerance ) Subjects may enroll certain concomitant nonbiologic DMARDs ( Methotrexate , Leflunomide , Sulfasalazine , Hydroxychloroquine ) provide medication use least 3 month stable dose least 28 day prior randomization ( Day 1 ) If use oral corticosteroid ( ≤10 mg mg/day Prednisone equivalent ) , dose must stable ≥14 day prior randomization ( Day 1 ) Subjects may enroll systemic retinoids ( eg : Acitretin ) provide medication use least 3 month stable dose least 28 day prior randomization ( Day 1 ) Subjects guttate , pustular , erythrodermic psoriasis Subjects prior exposure Abatacept ( CTLA 4Ig ) CTLA4 therapies Subjects expose investigational drug within 4 week 5 half life , whichever long Female subject breast cancer screen study suspicious malignancy , possibility malignancy reasonably exclude follow additional clinical , laboratory diagnostic evaluation Subjects history cancer within last 5 year ( nonmelanoma skin cell cancer cure local resection ) . Existing nonmelanoma skin cell cancer must remove prior dose . Subjects carcinoma situ , treat definitive surgical intervention prior study enrollment allow Subjects bacterial infection within last 60 day prior screen ( enrollment ) , unless treat resolved antibiotic , chronic bacterial infection ( chronic pyelonephritis , osteomyelitis bronchiectasis ) Subjects risk tuberculosis ( TB ) . Specifically , subject : Current clinical , radiographic laboratory evidence active TB A history active TB within last 3 year even treat A history active TB great 3 year ago unless documentation prior antiTB treatment appropriate duration type Latent TB successfully treat Subjects positive TB screen test indicative latent TB eligible study unless evidence current TB chest xray screen actively treat TB isoniazid ( INH ) therapy latent TB give accord local health authority guideline ( eg : Center Disease Control ) . Treatment must give least 4 week prior randomization ( Day 1 ) . These subject complete treatment accord local health authority guideline Subjects herpes zoster resolve less 2 month prior enrollment Subjects evidence ( measure investigator ) active latent bacterial , active viral , serious latent viral infection time enrollment , include subject evidence Immunodeficiency Virus ( HIV ) infection Subjects currently treat nonbiologic DMARD clinical radiographic evidence arthritis mutilans ( eg : digital telescope `` pencilincup '' radiographic change ) Subjects fail 2 TNFi due inefficacy define inadequate response 3 month treatment therapeutic dose Subjects receive TNFi therapy within 4 week etanercept within 8 week adalimumab , certolizumab , infliximab , golimumab Subjects receive prior use apremilast within 4 week , ustekinumab within 20 week briakinumab within 8 week Subjects discontinue nonbiologic DMARD systemic retinoid within four week five halflives , whichever longer , prior randomization ( Day 1 ) Use follow within 28 day five half live whichever long prior randomization ( Day 1 ) : Cyclosporine A , oral Tacrolimus , Mycophenolate Mofetil ( MMF ) , Hydroxyurea , Fumaric Acid Esters , Paclitaxel , 6Thioguanine , 6Mercatopurine , Tofacitinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>